Deltorphin
Overview
Deltorphin is a heptapeptide opioid agonist also derived from Phyllomedusa frog skin secretions, characterized by high selectivity for delta-opioid receptors. Like dermorphin, it contains an unusual D-amino acid residue that enhances metabolic stability and receptor affinity. Deltorphin exhibits analgesic properties distinct from mu-opioid agonists, with reduced respiratory depression and addiction liability in animal models. It has served as a pharmacological tool to elucidate delta-opioid receptor physiology and potential therapeutic roles.
Key Research Findings
Animal studies have shown potent antinociceptive effects with a more favorable side effect profile compared to morphine, particularly regarding respiratory suppression. Deltorphin analogs have been investigated to develop more stable and blood-brain barrier permeable compounds. Clinical translation has not occurred, and current use is limited to preclinical research applications.
Intracerebroventricular, Subcutaneous injection
Research Phase
Interested in Deltorphin?
Find a verified provider experienced with Deltorphin protocols in your area. All providers are credentialed and use compliant sourcing.
Find a Deltorphin ProviderRelated Peptides
Ziconotide (Prialt)
FDA ApprovedA synthetic 25-amino acid peptide identical to omega-conotoxin MVIIA, a neurotoxin found in the venom of the marine cone snail Conus magus. Ziconotide selectively and reversibly blocks N-type voltage-gated calcium channels (Cav2.2) in the dorsal horn of the spinal cord, inhibiting neurotransmitter release from primary afferent nociceptive neurons. It provides analgesia without opioid receptor activation, tolerance development, or respiratory depression.
Difelikefalin (Korsuva)
FDA ApprovedA selective kappa-opioid receptor (KOR) agonist peptide that does not cross the blood-brain barrier, providing peripheral analgesia and anti-pruritic effects without central opioid side effects such as euphoria, dysphoria, sedation, or addiction. Difelikefalin activates kappa receptors on peripheral sensory neurons and immune cells to reduce itch signaling and inflammation. Its restricted CNS penetration is a deliberate design feature to avoid abuse potential.
ARA-290
In Clinical TrialsA synthetic 11-amino acid peptide derived from the structure of erythropoietin (EPO) that selectively activates the innate repair receptor (IRR), a heteromer of the EPO receptor and the beta common receptor (CD131). Unlike EPO, ARA-290 does not stimulate erythropoiesis or promote thrombosis. It produces cytoprotective, anti-inflammatory, and tissue-reparative effects by activating the IRR on neurons, immune cells, and endothelial cells.
Palmitoylethanolamide (PEA)
Research PhaseAn endogenous fatty acid amide belonging to the N-acylethanolamine family, naturally produced by cells in response to tissue damage and inflammation. PEA acts primarily through peroxisome proliferator-activated receptor alpha (PPAR-alpha), downregulating mast cell activation and pro-inflammatory mediator release. It also modulates the endocannabinoid system via the entourage effect, enhancing anandamide activity at CB1/CB2 receptors and TRPV1 channels without directly binding cannabinoid receptors.